Kowa Company

CompanyJapanFounded 1894

Kowa Company develops one asset, in phase 3 (tofogliflozin in type 2 diabetes). Mostly small molecule acting on SLC5A2; based in Japan, founded in 1894.

1
Asset
Furthest: Phase 3; 2
Trials: 0
Signals

Pipeline

1

tofogliflozin
Selective SGLT2 inhibitor blocking renal glucose reabsorption
Phase 3, Small molecule, SLC5A2, type 2 diabetes

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials5
Similar companies6

Updated 9 Oct 2026 · 26 sources